Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback